ST百灵股票讨论区

Guizhou Bailing Group Pharmaceutical's high P/E ratio is backed by its robust forecast growth, outpacing the broader market. Investors are optimistic about the company's future prospects, keeping the stock in demand. The high P/E ratio will sustain the share price unless circumstances shift.